A Clinical Trial to Evaluate the Food Effect of CKD-379

Exclusion Criteria

• •1. A person who has taken a drug metabolase-inducing and inhibiting drug, such as barbitals, within 30 days before the start of the test (the first day of administration), or who has taken a drug that may interfere with the main test within 10 days before the start of the test (the first day of administration)
• •2. Anyone who has consumed excessive smoking or caffeine or alcohol within one month prior to the first administration of the clinical trial drug (caffeine: \> 5 cups/day, alcohol: male: \> 21 cups/week, female: \> 14 cups/week, tobacco: \> 20 cigarettes/day), or who cannot stop smoking, caffeine and alcohol consumption during each hospitalization period
• •3. Where the tester determines that the drug may affect the test or the safety of the subject, if the drug is administered within 14 days before the first administration of the clinical trial drug or the general drug including health food and vitamin preparations within 7 days
• •4. A person who has participated in clinical trials (including biological equivalence tests) and administered experimental drugs within 6 months before the start of the trial (the first dosing date)
• •5. A person who has donated whole blood within 8 weeks before the start of the test (the first medication date) or donated ingredients within 2 weeks or received a blood transfusion within 4 weeks
• •6. A person who has a history of gastrointestinal diseases (Cron's disease, ulcerative colitis, etc.) or surgery (excluding simple appendectomy or hernia surgery) that may affect the absorption of drugs
• •7. A person who has a clinically significant disease or mental illness corresponding to the biliary tract, kidney, nervous system, immune system, respiratory system, urinary system, digestive system, endocrine system, blood and tumor, cardiovascular system, musculoskeletal system, or has the following manifestations or past history
• •* Patients with type 1 diabetes, acute or chronic metabolic acidosis, and those with a history of ketoacidosis (including diabetic ketoacidosis), diabetic comas and total marriages, lactic acidosis, etc
• •* Patients with severe heart failure or a history of heart failure (New York Heart Association (NYHA) classification 1,2,3,4 heart conditions)
• •* liver dysfunction
• •* Patients with moderate to severe renal impairment (eGFR \<60 mL/min/1.73 m2)
• •* Patients undergoing tests for intravenous administration of radioiodine contrast agents
• •* Before and after 48 hours of surgery, patients with dehydration, severe infection or severe traumatic systemic disorder, acute myocardial infarction, sepsis
• •* patients with malnutrition, starvation, weakness, pituitary dysfunction or adrenal insufficiency
• •* As a result of performing a diagnostic test at the time of screening, a person who shows the following figures: AST or ALT or total bilirubin more than twice the upper limit of normal range
• •8. A person who has a history of clinically significant hypersensitivity reactions to other drugs or additives, including clinical trial drug
• •9. A person who has a history of drug abuse within one year of screening
• •10. In the case of women who are pregnant women and pregnant women who are pregnant or pregnant
• •11. A person who determines that the investigator is not suitable for participating in the clinical trial due to other reasons